Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization, Inc. announced positive 24-month Phase 3 VISIONARY results for VOYXACT, or sibeprenlimab-szsi, in adults with primary immunoglobulin A nephropathy at risk of disease progression. The selective APRIL inhibitor produced statistically significant stabilization of estimated glomerular filtration rate, showed evidence of improved kidney function and reduced the risk of progression toward kidney failure, completing the confirmatory dataset intended to support traditional U.S. approval.
The importance of the announcement extends beyond another positive IgA nephropathy trial. VOYXACT already has accelerated approval based on its ability to reduce proteinuria, but the central clinical and regulatory question has always been whether that early surrogate benefit would translate into slower deterioration of kidney function. The two-year VISIONARY result moves Otsuka closer to answering that question, although the absence of detailed numerical results means the size and consistency of the benefit cannot yet be independently assessed.
Why the two-year eGFR result matters more than another proteinuria reduction headline
Proteinuria has become a useful pathway for accelerating the development of IgA nephropathy therapies because elevated urine protein is strongly associated with disease progression. Reducing proteinuria can therefore provide an early signal that a treatment is modifying kidney injury. It does not, however, automatically prove that patients will retain kidney function or avoid dialysis and transplantation over the longer term.
VOYXACT received accelerated U.S. approval in November 2025 after the VISIONARY trial showed a substantial reduction in urine protein-to-creatinine ratio after nine months. The approved indication remains limited to reducing proteinuria because long-term kidney function preservation had not been established when the original application was reviewed.
The 24-month eGFR findings are consequently more consequential than the earlier proteinuria result. Estimated glomerular filtration rate measures how effectively the kidneys filter blood, making its trajectory more directly relevant to the progression of chronic kidney disease. A treatment that meaningfully changes the slope of eGFR decline could delay advanced kidney disease even when the trial is not long enough to observe large numbers of dialysis or transplantation events.
Earlier VISIONARY data provided an encouraging bridge between proteinuria reduction and kidney preservation. At 12 months, patients receiving VOYXACT had a mean eGFR change from baseline of positive 0.7 mL/min/1.73 m², compared with a decline of 4.8 mL/min/1.73 m² in the placebo group. The estimated annualized eGFR slope was negative 3.0 with VOYXACT and negative 7.6 mL/min/1.73 m² per year with placebo.
The final analysis now indicates that the separation persisted through two years and that kidney function may have improved relative to baseline. That durability is important because short-term eGFR movements can be influenced by haemodynamic effects, measurement variability and changes in supportive therapy. Persistence over 24 months makes a transient explanation less likely, although the complete analyses will still be needed to determine how much of the benefit arose early and whether it remained stable throughout follow-up.
How selective APRIL inhibition could reposition treatment around upstream disease biology
VOYXACT is a humanized monoclonal antibody designed to block A proliferation-inducing ligand, commonly known as APRIL. This immune signalling protein supports the survival and activity of antibody-producing cells involved in generating galactose-deficient immunoglobulin A1, a central component in the current biological model of IgA nephropathy.
Galactose-deficient immunoglobulin A1 can trigger the formation of immune complexes that accumulate in the kidneys, promote inflammation and progressively damage the glomeruli. By reducing the production of this abnormal immunoglobulin A, selective APRIL inhibition attempts to intervene near the beginning of the disease process rather than managing only the resulting protein leakage, blood pressure changes or inflammatory injury.
This mechanistic position could distinguish VOYXACT within an increasingly segmented IgA nephropathy market. Targeted-release budesonide acts primarily on mucosal immune activity in the gut. Sparsentan and atrasentan address endothelin-related and haemodynamic pathways. Iptacopan inhibits the alternative complement pathway. VOYXACT instead targets an upstream immune driver connected to pathogenic immunoglobulin A production.
That differentiation does not establish superiority. VISIONARY did not directly compare VOYXACT with targeted-release budesonide, sparsentan, iptacopan or atrasentan, and cross-trial comparisons are complicated by differences in baseline proteinuria, kidney function, background treatment and endpoint definitions. The new results support APRIL inhibition as a credible therapeutic strategy, but they cannot determine which mechanism should be preferred for a particular patient.
The broader commercial opportunity may therefore involve treatment combinations rather than simple replacement. IgA nephropathy includes immune activation, immune-complex deposition, complement signalling, inflammation and pressure-related kidney injury. A drug targeting pathogenic immunoglobulin A production could potentially be used alongside therapies addressing haemodynamic stress or other downstream pathways. Such combinations will require clinical evidence because overlapping treatment may increase costs, monitoring requirements and safety complexity.
Why the VISIONARY trial design adds regulatory weight but does not remove uncertainty
VISIONARY is a global, randomized, double-blind, placebo-controlled Phase 3 study evaluating VOYXACT in adults with biopsy-confirmed IgA nephropathy. Participants received 400 mg of sibeprenlimab-szsi or placebo by subcutaneous injection once every four weeks while continuing appropriate background therapy.
The study’s original primary efficacy endpoint measured the change in 24-hour urine protein-to-creatinine ratio after nine months. Annualized eGFR slope over 24 months served as the key secondary endpoint, while mean change in eGFR at month 24 provided a complementary measure of kidney function.
Using both eGFR slope and change from baseline strengthens the analysis because the measurements answer related but different questions. The slope evaluates the trajectory of kidney function across repeated assessments, while the month 24 comparison examines the total difference reached at a specific time. Consistent findings across both endpoints would make the result more persuasive than reliance on either measure alone.
The placebo-controlled design also allows Otsuka to estimate the incremental effect of selective APRIL inhibition on top of contemporary supportive care. This matters because the underlying standard of care has improved, particularly through optimized renin-angiotensin system blockade and growing use of sodium-glucose cotransporter-2 inhibitors. Demonstrating an additional benefit in that environment may be harder, but it also makes a positive result more relevant to current practice.
Important uncertainties remain. Otsuka has not disclosed the numerical 24-month eGFR slopes, treatment difference, confidence intervals or statistical values. The announcement also lacks absolute kidney-failure event counts, the definition used for the progression endpoint and information about whether the reported risk reduction was consistent across sensitivity analyses.
Retention and missing-data handling will warrant particular attention because kidney trials extending over two years can be affected by treatment discontinuations, rescue therapy, changes in supportive care and incomplete laboratory measurements. Regulators and clinicians will also examine whether the effect was consistent across geographic regions, baseline eGFR categories, proteinuria levels and use of sodium-glucose cotransporter-2 inhibitors.
Until those analyses are presented at a scientific meeting or published in a peer-reviewed journal, the result should be viewed as an important positive topline outcome rather than a fully interpretable dataset.
What VOYXACT’s safety profile could mean for prolonged immune-targeted treatment
Otsuka reported that the final safety profile remained consistent with earlier VISIONARY findings and was comparable with placebo. That continuity is commercially relevant because IgA nephropathy is a chronic disease often diagnosed in younger adults who may require prolonged treatment to preserve kidney function.
The current prescribing information nevertheless identifies immunosuppression and infection risk as important considerations. In the dataset supporting accelerated approval, infections occurred in 49 percent of patients receiving VOYXACT and 45 percent receiving placebo. Injection-site reactions occurred in 24 percent and 23 percent, respectively, with most adverse reactions described as mild or moderate.
Selective APRIL inhibition is designed to reduce pathogenic antibody production without broadly depleting B cells. This could offer a more focused immunological intervention than therapies causing extensive immune-cell depletion. Selectivity, however, does not eliminate immune consequences. Reduced antibody production may affect infection susceptibility and vaccine responses, while live vaccines are not recommended shortly before or during treatment.
Longer observation will be needed to evaluate less common or cumulative safety issues. The open-label extension study should provide evidence about sustained immunoglobulin changes, serious infections, discontinuation rates and whether efficacy is maintained with continued monthly dosing. Pregnancy data, outcomes in older adults and experience in patients with recurring infections also remain limited.
The safety question will become more complicated if VOYXACT is used with other disease-modifying therapies. Individual treatments may have manageable profiles when administered alone, but combinations could produce unexpected effects on immunity, blood pressure, fluid balance or infection risk. Future studies will need to establish whether mechanistic complementarity translates into an acceptable overall benefit-risk profile.
How the findings could influence VOYXACT’s full FDA approval pathway
The VISIONARY result directly addresses the outstanding condition attached to VOYXACT’s accelerated approval. The U.S. Food and Drug Administration permitted earlier market access based on proteinuria reduction while requiring confirmation that the medicine slows long-term kidney function decline.
Otsuka has initiated a rolling supplemental Biologics License Application seeking traditional approval and plans to add the complete 24-month findings. A rolling process allows completed portions of an application to be submitted before the full package is assembled, potentially making the regulatory review more efficient once all required data are available.
A positive confirmatory study does not make conversion automatic. The U.S. regulator will review the magnitude and robustness of the eGFR benefit, statistical analysis plan, missing-data assumptions, safety findings, manufacturing information and consistency between the proteinuria and kidney-function results. The agency will also determine whether the final data justify revised wording that explicitly states VOYXACT slows kidney function decline.
The full dataset could support broader applications outside the United States as well. Regulatory agencies may differ in how they evaluate proteinuria, eGFR slope and the clinical relevance of treatment effects. Otsuka will need to show that the results are applicable across regions and that manufacturing capacity can support wider commercial availability of a biologic administered every four weeks.
Traditional approval would remove a central uncertainty surrounding VOYXACT and strengthen its positioning against therapies that already carry kidney-function indications. Failure to secure suitable label language would not necessarily eliminate the product’s commercial role, but it could make differentiation and reimbursement more difficult in a market where several medicines already reduce proteinuria.
Why commercial adoption will depend on sequencing, reimbursement and administration
VOYXACT’s once-every-four-weeks subcutaneous administration offers a different treatment experience from daily oral medicines. Self-administration may reduce the need for infusion-centre visits and could be attractive for patients comfortable using injectable biologics. Monthly dosing may also support adherence compared with medicines requiring multiple daily capsules.
Oral competitors may retain an advantage among patients who prefer tablets or wish to avoid injections. Clinicians must also consider differences in contraindications, monitoring, pregnancy precautions and interactions with existing supportive therapy. Administration convenience will therefore be only one part of treatment selection.
Payers are likely to demand clear evidence that VOYXACT provides durable kidney protection and reduces the likelihood of costly advanced disease. The eventual eGFR effect size, number needed to treat, duration of benefit and performance in higher-risk subgroups could influence coverage criteria. Access may initially be concentrated among adults with persistent proteinuria or declining kidney function despite optimized supportive care.
Treatment sequencing remains unresolved. VOYXACT may be positioned as an early targeted intervention because APRIL activity is associated with the upstream production of pathogenic immunoglobulin A. Alternatively, reimbursement policies could require patients to receive established supportive and oral therapies before moving to a biologic.
Biomarkers could eventually help refine selection, particularly if baseline galactose-deficient immunoglobulin A1 levels or their reduction during treatment predict kidney outcomes. The VISIONARY dataset may provide clues, but biomarker-guided prescribing would require validated thresholds and evidence that testing improves clinical decision-making.
What clinicians, regulators and industry observers will watch after the topline result
The next decisive disclosure will be the complete 24-month analysis. Attention will centre on the annualized eGFR slopes in each arm, the absolute treatment difference, confidence intervals, sensitivity analyses and the proportion of patients experiencing clinically important declines in kidney function.
Kidney-failure progression data require particular scrutiny. Otsuka described a robust reduction in the risk of progression, but no event numbers or effect estimates were provided. Because kidney failure develops over many years in numerous patients with IgA nephropathy, a two-year study may record relatively few such events. Composite endpoints can increase statistical power but must be interpreted according to their individual components.
Researchers will also examine whether proteinuria reduction predicted later eGFR preservation. A strong relationship would reinforce proteinuria as an effective surrogate endpoint for future IgA nephropathy development programmes. A weaker relationship could suggest that additional biomarkers or longer follow-up are needed to identify therapies that genuinely alter disease progression.
For the wider biotechnology industry, the result strengthens interest in the APRIL and B-cell survival pathways. A successful regulatory conversion could validate selective APRIL inhibition as a commercial drug class and intensify competition among developers targeting APRIL, B-cell activating factor or both signalling proteins.
The overall direction is favourable for Otsuka, but the distinction between a positive announcement and a practice-changing dataset remains important. VISIONARY appears to have cleared the central confirmatory hurdle facing VOYXACT. The scale of the kidney benefit, its durability, its performance across patient groups and its value relative to existing therapies will determine whether VOYXACT becomes a foundational treatment or one component of a more complex IgA nephropathy strategy.
